An RFP process has been developed to identify early-stage Vanderbilt therapeutic development projects, which will be utilized to select promising research opportunities by the Vanderbilt Selection Committee, and managed by the Vanderbilt-Ancora Joint Operations Committee. Development of selected projects will be supported by Ancora, advancing them from their existing state through the pre-clinical development process — including basic research, proof of concept, target selection and investigational new drug (IND)-enabling studies designed to qualify a candidate to enter into human clinical